Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Menlo Therapeutics Inc (MNLO)

Menlo Therapeutics Inc (MNLO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 226,383
  • Shares Outstanding, K 167,691
  • Annual Sales, $ 0 K
  • Annual Income, $ -73,700 K
  • 60-Month Beta 1.07
  • Price/Sales 5.76
  • Price/Cash Flow N/A
  • Price/Book 3.16
Trade MNLO with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.75
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 10/29/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.18
  • Number of Estimates 2
  • High Estimate -0.17
  • Low Estimate -0.19
  • Prior Year -0.70
  • Growth Rate Est. (year over year) +74.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3000 +3.85%
on 09/04/20
1.8500 -27.03%
on 08/05/20
-0.4200 (-23.73%)
since 08/04/20
3-Month
1.3000 +3.85%
on 09/04/20
2.3700 -43.04%
on 06/19/20
-0.8600 (-38.91%)
since 06/04/20
52-Week
1.0000 +35.00%
on 04/08/20
7.4800 -81.95%
on 01/17/20
-3.4700 (-71.99%)
since 09/04/19

Most Recent Stories

More News
VYNE Therapeutics (formerly Menlo Therapeutics) to Present at the Cantor Fitzgerald and H.C. Wainwright Investment Conferences in September

VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company") today announced that David Domzalski, Chief Executive Officer, will present at the upcoming H.C. Wainwright 22 Annual Global Investment Conference...

MNLO : 1.3500 (-2.17%)
VYNE : 1.9200 (+5.49%)
Menlo Therapeutics Announces Completion of Corporate Name Change to VYNE Therapeutics

, /PRNewswire/ -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company") today completed its previously announced corporate name change from Menlo Therapeutics Inc. to VYNE Therapeutics Inc....

MNLO : 1.3500 (-2.17%)
VYNE : 1.9200 (+5.49%)
Menlo Therapeutics Announces Corporate Name Change to VYNE Therapeutics

Company will commence trading under new ticker "VYNE" on September 8, 2020

MNLO : 1.3500 (-2.17%)
Menlo Therapeutics Inc. (MNLO) Reports Q2 Loss, Tops Revenue Estimates

Menlo Therapeutics Inc. (MNLO) delivered earnings and revenue surprises of -476.19% and 472.94%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?...

MNLO : 1.3500 (-2.17%)
Menlo Therapeutics Announces Pricing of Offering of Common Stock

Menlo Therapeutics Inc. ("Menlo") (Nasdaq: MNLO), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced...

MNLO : 1.3500 (-2.17%)
Menlo Therapeutics Announces Proposed Offering of Common Stock

Menlo Therapeutics Inc. ("Menlo") (Nasdaq: MNLO), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced...

MNLO : 1.3500 (-2.17%)
Menlo Therapeutics Announces Positive Results from Phase 2 Trial of FCD105 for the Treatment of Moderate-to-Severe Acne Vulgaris

Menlo Therapeutics Inc. (Nasdaq: MNLO) ("Menlo" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology,...

MNLO : 1.3500 (-2.17%)
Menlo Therapeutics Receives FDA Approval of ZILXI™ (minocycline) topical foam, 1.5%, the First Topical Minocycline Treatment for Rosacea

, /PRNewswire/ -- Menlo Therapeutics Inc. (Nasdaq: MNLO) ("Menlo" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet...

FOMX : 2.99 (-7.72%)
MNLO : 1.3500 (-2.17%)
Menlo Therapeutics Receives FDA Approval of ZILXI(TM) (minocycline) topical foam, 1.5%, the First Topical Minocycline Treatment for Rosacea

Menlo Therapeutics Inc. (Nasdaq: MNLO) ("Menlo" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology,...

FOMX : 2.99 (-7.72%)
MNLO : 1.3500 (-2.17%)
Menlo Therapeutics (MNLO) Catches Eye: Stock Jumps 7.1%

Menlo Therapeutics (MNLO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

AGLE : 8.03 (+3.35%)
MNLO : 1.3500 (-2.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Menlo Therapeutics Inc. is a late stage biopharmaceutical company. It focused on the development of serlopitant and treatment of chronic itch and chronic refractory cough. The company's product pipeline consists of Prurigo Nodularis Itch, Atopic Dermatitis Itch, Psoriasis Itch and Refractory Chronic...

See More

Key Turning Points

2nd Resistance Point 1.4367
1st Resistance Point 1.3933
Last Price 1.3500
1st Support Level 1.3033
2nd Support Level 1.2567

See More

52-Week High 7.4800
Fibonacci 61.8% 5.0046
Fibonacci 50% 4.2400
Fibonacci 38.2% 3.4754
Last Price 1.3500
52-Week Low 1.0000

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar